Food and Drug Administration Commissioner Scott Gottlieb, MD, testified Thursday before the House Appropriations Subcommittee, discussing President Donald Trump's proposed budget, the FDA hiring freeze and strategies to lower drug prices, reports Regulatory Focus.
Here are four things to know.
- Dr. Gottlieb said President Trump's federal hiring freeze no longer applies to the FDA.
- The FDA head responded to criticism surrounding the proposed budget, saying he was not involved with developing the budget proposal, according to the report.
- Dr. Gottlieb said he will soon share a "drug competition action plan" and a list of off-patent drugs with no current generic competition.
- He also said the FDA plans to update its risk evaluation and mitigation strategy regulations — which ensure the benefits of a drug or biologic outweigh its risks — to prevent drugmakers from taking advantage of the rules for their own benefit, reports Regulatory Focus.
More articles on supply chain:
Supply chain tip of the day: Schedule daily huddles with surgical teams
Controversial bill addressing diabetes drug prices reaches Nevada governor's desk: 5 things to know
Marijuana-derived epilepsy drug nears FDA approval